Editors’ Picks, March 2024: Synergy’s Impact on Resistance, New Early Detection Tools, and More
March's picks include how synergy drives drug resistance in AML, new early detection tools, and more.
March's picks include how synergy drives drug resistance in AML, new early detection tools, and more.
This Trojan horse-like treatment strategy may help neutralize undruggable cancer drivers.
Researchers are finding early clinical success in developing more targeted treatments for bile duct cancer, also called cholangiocarcinoma.
Molecular profiling of individual cancers can determine who needs what treatment, and who can avoid certain treatments and complications....
Recent studies found awareness gaps about cancer prevention strategies such as screening and vaccination may reduce who benefits from...
January’s selections include disparities in genetic testing, updates from a breast cancer clinical trial, and more.
Patricia M. LoRusso and Stacy Shord discuss dosage optimization's current state and how the FDA-AACR workshop will move the...
This quarter’s new tools and strategies for cancer research included molecular jackhammers and biobots that crawl.
The AACR supports the mission of World Cancer Day 2024 to Close the Care Gap, which it has worked...
In part 4 of our 2024 Experts Forecast, Paul Workman, PhD, shares thoughts on cutting-edge advances in oncology drug...
In part 3 of our 2024 Experts Forecast, AACR President-Elect Patricia M. LoRusso, DO, PhD (hc), FAACR, shares thoughts...